Rubius Therapeutics RI Expansion Underway
Renovated Facility to Support Next Gen Cellular Therapy Development
A/Z Corporation has partnered with Rubius Therapeutics to support the development of its ground-breaking Red-Cell Therapeutics (RCTs™) with a new facility in Smithfield, RI.
Rubius’ innovative therapies utilize genetically engineered, enucleated red blood cells to treat rare disease, eliminate tumors, and regulate the immune system. Its RED PLATFORM™ manufacturing process boasts outstanding efficiency with the ability to produce allogenic products that can treat thousands of patients from a single universal donor. The company is intending to purchase a 135,000-square foot manufacturing facility in Smithfield, RI that will be used to scale-up its manufacturing process.
Drawing on our extensive experience in the biopharmaceutical regulated manufacturing sector, A/Z is collaborating with design partners to help Rubius plan the renovations necessary to prepare this new facility. The work is expected to include the development of multiple CGMP-compliant manufacturing suites. Ultimately, Rubius is planning to invest up to $155 million in the campus and hire approximately 150 people at the facility.
Rubius’ CEO Pablo Cagnoni remarked on the importance of this latest move for the company: “The acquisition of the Rhode Island manufacturing facility is a critical step toward making the promise of Red Cell Therapeutics a reality. We believe that by owning our manufacturing capabilities and controlling our supply chain we will be prepared to scale up manufacturing of clinical and potentially commercial supply of our novel therapies.”
The redevelopment of the Smithfield site is a tremendously exciting opportunity for both Rubius and the State of Rhode Island, and A/Z is proud to be a part of the program. Rubius’ announcement to utilize this facility and local news coverage can be found below:
Rubius Therapeutics: Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield…
Rhode Island Inno: It’s Official: Rubius Therapeutics to Build Smithfield Manufacturing Plan